We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




GlaxoSmithKline and Yale Establish Drug Discovery Collaboration to Create a New Class of Chimeric Molecules

By LabMedica International staff writers
Posted on 08 May 2012
Print article
GlaxoSmithKline, plc (GSK; Brentford, UK) and Yale University (New Haven, CT, USA) have initiated a drug discovery research collaboration to design a possible new class of medicines that degrade disease-causing proteins.

The collaboration combines GSK’s expertise in medicinal chemistry with Yale’s innovative research on proteolysis-targeting chimeric molecules (PROTACs). PROTAC technology guides disease-causing proteins to a cell’s “trash can,” where they can be destroyed. Mutant or higher-than normal amounts of these proteins typically fuel disease progression in areas such as oncology, inflammation, and infections; however, many cannot be tackled by conventional ways of making drugs.

Under the agreement, a joint research team will attempt to show that PROTACs can be transformed into future medicines. GSK will then have the right to use this technology for multiple disease-causing proteins across all therapy arenas. For each protein-degrading agent that is found and developed, Yale will be eligible for milestone and royalty payments. Several collaborations between GSK and UK-based universities have been reported that also involve such joint research towards common milestones, combined with an element of risk sharing by the parties. This partnership differs through its scope around a potential new class of medicines and because of its association with a US academic center.

“This partnership is exploring a new way for promising, but unproven therapeutic approaches to jump from the academic lab more quickly into the early stage pharmaceutical pipeline,” said Kris Famm, head of GSK’s protein degradation effort, who will lead the program with Dr. Craig Crews, a professor of molecular, cellular, and developmental biology, and professor of chemistry and pharmacology at Yale. “The ground-breaking work Craig and his team have done may allow us to tackle a whole host of disease-causing proteins that were previously out of reach for medicines, and it is exciting to work together to try to realize that promise.”

The collaboration has been authorized by GSK’s discovery investment board, the panel of internal and external experts who make funding decisions on GSK’s small biotech-like discovery performance units (DPUs). The collaborative work with GSK and Yale is now underway, with the objective of showing critical proof of principle for this technology by the end of 2012. “The relationship between the pharmaceutical industry and academia is changing,” Dr. Crews concluded, “and this collaboration offers a new paradigm for how pharma companies and academic researchers can benefit from working more closely together.”

Related Links:

GlaxoSmithKline
Yale University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.